Unknown

Dataset Information

0

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019.

ABSTRACT: We characterized the antibody composition of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) and the immunologic responses of hospitalized COVID-19 patients after receiving CCP or nonimmune fresh frozen plasma. Despite selection of CCP with significantly higher total immunoglobulin G than recipients, neutralizing antibody levels did not differ between donor plasma and CCP recipients.

SUBMITTER: Bainbridge ED 

PROVIDER: S-EPMC8344822 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019.

Bainbridge Emma D ED   Hsue Priscilla Y PY   Esensten Jonathan H JH   Lynch Kara L KL   Hendrickson Carolyn M CM   Doernberg Sarah B SB   Fung Monica M   Chin-Hong Peter P   Di Germanio Clara C   Norris Philip J PJ   Simmons Graham G   Glidden David V DV   Luetkemeyer Anne F AF  

Open forum infectious diseases 20210716 8

We characterized the antibody composition of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) and the immunologic responses of hospitalized COVID-19 patients after receiving CCP or nonimmune fresh frozen plasma. Despite selection of CCP with significantly higher total immunoglobulin G than recipients, neutralizing antibody levels did not differ between donor plasma and CCP recipients. ...[more]

Similar Datasets

Unknown Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
| S-EPMC8083369 | biostudies-literature
Unknown Convalescent Plasma for Patients With Severe Coronavirus Disease 2019 (COVID-19): A Matched Cohort Study.
| S-EPMC7665324 | biostudies-literature
Unknown Convalescent plasma: possible therapy for novel coronavirus disease 2019.
| S-EPMC7267548 | biostudies-literature
Unknown Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
| S-EPMC7454720 | biostudies-literature
Unknown Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy.
| S-EPMC7536086 | biostudies-literature
Unknown Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.
| S-EPMC7717355 | biostudies-literature
Unknown Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma.
| S-EPMC7251400 | biostudies-literature
Unknown Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy.
| S-EPMC9082011 | biostudies-literature
Unknown A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019.
| S-EPMC10552585 | biostudies-literature
Unknown Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.
| S-EPMC9658886 | biostudies-literature